Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
Sponsor: InventisBio Co., Ltd
Summary
D-0120 is being tested in combination with Allopurinol in adult subjects with Gout.
Official title: A Randomized, Open-Label, Multiple-Dose Phase II Study to Evaluate Efficacy and Safety of D-0120 Administered in Combination With Allopurinol in Subjects With Gout
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2023-04-17
Completion Date
2025-12-30
Last Updated
2025-05-08
Healthy Volunteers
No
Conditions
Interventions
D-0120
increasing dose of D-0120
Allopurinol
standard dosing
Locations (19)
Study Center
Birmingham, Alabama, United States
Site Center
Plantation, Florida, United States
Study Center
Evergreen Park, Illinois, United States
Study Center
Brownsburg, Indiana, United States
Site Center
Louisville, Kentucky, United States
Study Center
Hickory, North Carolina, United States
Study Center
Rocky Mount, North Carolina, United States
Study Center
Salisbury, North Carolina, United States
Study Center
Wilmington, North Carolina, United States
Study Center
Winston-Salem, North Carolina, United States
Study Center
Scottdale, Pennsylvania, United States
Study Center
Bristol, Tennessee, United States
Site Center
Hendersonville, Tennessee, United States
Study Center
Knoxville, Tennessee, United States
Site Center
Fort Worth, Texas, United States
Site Center
The Woodlands, Texas, United States
Site Center
Richmond, Virginia, United States
Site Center
Bellevue, Washington, United States
Study Center
Morgantown, West Virginia, United States